The Non-viral Transfection Reagents and Systems Market is anticipated to grow at a CAGR of ~10% till 2035, claims Roots Analysis
Non-viral vectors have emerged as an effective and safe delivery vehicle for genetically-modified therapies; the growing interest in these vectors has further resulted in an increase in demand for versatile transfection reagents and systems
LONDON, June 15, 2023 /PRNewswire/ -- Roots Analysis has announced the addition of "Non-Viral Transfection Reagents and Systems Market, 2nd Edition, 2023-2035" report to its list of offerings.
With increasing focus on genetically modified therapies, there is a consequent rise in the demand for efficient gene delivery vectors and innovators are actively evaluating the potential of non-viral transfection agents. Driven by the growing demand for cell and gene therapies, and the ongoing efforts of industry stakeholders, the non-viral transfection reagents and systems market is anticipated to grow at a steady pace in the foreseen future.
To order this 275+ pages report, which features 120+ figures and 140+ tables, please visit the link
Key Market Insights
More than 185 non-viral transfection reagents are being offered by ~55 players
Around 85% of the reagents assist in delivering DNA molecules, while more than 50% reagents are used for the delivery of RNA molecules. Further, it is worth highlighting that ~60% of these transfection reagents use lipids as the preferred carriers for gene delivery.
Over 20 electroporation-based transfection systems are offered by more than 10 players
Majority of the electroporation-based transfection system providers are headquartered in North America (75%), followed by those based in Asia-Pacific (17%) and Europe (8%). More than 50% of these system providerss were established pre-2000.
Close to 40 other non-viral transfection systems have been commercialized
More than 90% of the available systems are compatible with human cells and cell lines. Further, more than 65% of these platforms are capable of transfection of both types of molecules (DNA and RNA).
Since 2019, 860+ patents have been filed / granted for non-viral transfection reagents and systems
Close to 70% of the patents are being processed as applications, while around 30% of the total patents filed have been granted. Majority (50%) of the patents have been filed by applicants based in North America.
More than 450 articles focused on non-viral transfection have been published in the recent years
Nearly 70% of the aforementioned publications are research articles, while the remaining are review articles related to the non-viral transfection reagents and systems. Most of the articles were focused on the delivery of DNA molecules via non-viral transfection reagents.
Several big pharma players have undertaken various types of initiatives related to non-viral transfection systems, between 2017 and 2022
Of all the recent big pharma initiatives, close to 80% were collaborations; of these, ~70% were for research and development purposes. Further, ~60% of the initiatives were focused on the development of oncological cell and gene therapies.
North America and Europe are anticipated to capture over 75% of the market share, by 2035
The market in Asia-Pacific and rest of the world is anticipated to grow at a relatively faster pace and occupy ~25% of the total market in 2035. Further, academic and research institutes are making the maximum contribution (over 50%) to the non-viral transfection reagents and systems market, followed by pharma and biotech companies (~45%).
To request a sample copy / brochure of this report, please visit this link
Key Questions Answered
- How is the research and development (R&D) activity evolving in the non-viral transfection reagents and systems market?
- How many companies offer non-viral transfection reagents and systems?
- What are the different types of initiatives being undertaken by big pharma players for the manufacturing of non-viral transfection reagents and systems?
- Which segment is likely to capture the largest share in the non-viral transfection reagents and systems market?
- How is the non-viral transfection reagents and systems market likely to evolve in the coming years?
The future opportunity within the non-viral transfection reagents and systems market has been analyzed across the following segments:
- Non-Viral Based Transfection Methods
- Chemical-based Methods
- Physical-based Methods
- Other Methods
- End-Users
- Academic And Research Institutions
- Stem Pharmaceutical Companies
- Other End-Users
- Area Of Application
- Clinical Applications
- Research Applications
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
The report includes detailed profiles of key players (listed below) engaged in the development of non-viral transfection reagents and systems; each profile features an overview of the developer, financial information (if available), details related to its product portfolio, recent developments, and an informed future outlook:
- BEX
- Bio-Rad Laboratories
- BTX
- Celsion Corporation
- Genprex
- Inovio Pharmaceuticals
- MaxCyte
- MilliporeSigma
- NepaGene
- OZ Biosciences
- Thermo Fisher Scientific
For additional details, please visit https://www.rootsanalysis.com/reports/view_document/non-viral-transfection/307.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
- Cell Therapy Manufacturing Market: Industry Trends and Global Forecasts (5th Edition), 2022-2035
- Adeno Associated Viral Vector / AAV Vector Market: Industry Trends and Global Forecast, 2022-2035
- Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market: Industry Trends and Global Forecast, 2022-2035 (5th Edition)
- Gene Therapy Market by Type of Therapy: Industry Trends and Global Forecasts (5th Edition), 2022-2035
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg
Share this article